Edward G. Broenniman, a director at Aethlon Medical Inc, has reported a transaction involving the forfeiture of 218 shares of the company's common stock. This event is significant as it highlights the ongoing adjustments in executive compensation practices within the surgical and medical instruments industry.
Broenniman's transaction occurred on September 30, 2026, and was officially reported on October 15, 2026. The forfeiture was necessary to cover tax withholdings related to the conversion of restricted stock units into shares of common stock. This reflects a broader trend of transparency in stock ownership among executives, particularly in industries like medical instruments where regulatory scrutiny is high.
Background
Aethlon Medical Inc, identified by the Central Index Key (CIK) 0000882291, operates in the surgical and medical instruments sector. The company is incorporated in Nevada and has its business address in San Diego, California. Aethlon Medical is publicly traded under the ticker symbol AEMD.
What the Filing Says
The SEC filing indicates that Broenniman forfeited 218 shares to cover tax obligations from the conversion of 1,091 vested and outstanding restricted stock units. The filing notes, "These restricted stock units were part of the grant reported in Table I of the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on April 17, 2026." Following this transaction, Broenniman owns 4,313 shares of Aethlon Medical.
Impact
This transaction may affect Aethlon Medical's shareholders and potential investors, as it reflects the company's approach to managing executive compensation and stock ownership. The transparency demonstrated by Broenniman's filing can enhance investor confidence in the company's governance practices.
What's Next
The filing does not say what happens next.